Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Abstract

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

1 . A drug delivery system comprising: a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is an intraocular pressure lowering agent, a neurotrophic agent, a C-type Natriuretic Peptide (CNP), a Natriuretic Peptide Receptor-B (NPR-B), an apoptosis signaling fragment (FAS) inhibitor or a FAS-ligand (FASL) inhibitor, or a combination thereof. 
     
     
         2 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the intraocular pressure lowering agent and the second API is the neurotrophic agent. 
     
     
         3 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the intraocular pressure lowering agent and the second API is the CNP. 
     
     
         4 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the intraocular pressure lowering agent and the second API is the NPR-B. 
     
     
         5 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the intraocular pressure lowering agent and the second API is the FAS inhibitor or the FASL inhibitor. 
     
     
         6 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the neurotrophic agent and the second API is the CNP. 
     
     
         7 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the neurotrophic agent and the second API is the NRP-B. 
     
     
         8 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the neurotrophic agent and the second API is the FAS inhibitor or the FASL inhibitor. 
     
     
         9 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the CNP and the second API is the NRP-B. 
     
     
         10 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the CNP and the second API is the FAS inhibitor or the FASL inhibitor. 
     
     
         11 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is the NRP-B and the second API is the FAS inhibitor or the FASL inhibitor. 
     
     
         12 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API and the second API are not covalently bonded to one another. 
     
     
         13 . The drug delivery system of  claim 1 , further comprising a second API, wherein the first API is covalently bonded to the second API. 
     
     
         14 . The drug delivery system of  claim 1 , wherein the first API is covalently bonded to the sustained delivery component. 
     
     
         15 . The drug delivery system of  claim 1 , further comprising a second API, wherein the second API is covalently bonded to the sustained delivery component. 
     
     
         16 . The drug delivery system of  claim 1 , having about 100 μg to about 1 mg of the first API. 
     
     
         17 . The drug delivery system of  claim 1 , further comprising a second API, having about 100 μg to about 1 mg of the second API. 
     
     
         18 . The drug delivery system of  claim 1 , wherein the implant has a weight of about 300 μg to about 10 mg. 
     
     
         19 . A method of treating a glaucoma comprising administering a drug delivery system of  claim 1 , to a mammal in suffering from glaucoma or ocular hypertension. 
     
     
         20 . The method of  claim 19 , wherein the drug delivery system is injected into an eye of the mammal, and wherein the mammal is a human being. 
     
     
         21 .- 26 . (canceled)